search
Back to results

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

Primary Purpose

Ulcerative Colitis

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
adalimumab
Sponsored by
AbbVie (prior sponsor, Abbott)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ulcerative Colitis focused on measuring Ulcerative Colitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject must have successfully enrolled and completed either study M06-826 (NCT00385736) or study M06-827 (NCT00408629)
  • Subject is judged to be in generally good health as determined by the principal investigator

Exclusion Criteria:

  • Subject has not responded to weekly adalimumab therapy in M06-826 (NCT00385736) or M06-827 (NCT00408629)
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Adalimumab 40 mg EOW/EW

    Arm Description

    Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.

    Outcomes

    Primary Outcome Measures

    Partial Mayo Score: Change From Baseline Over Time
    The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment [PGA]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Partial Mayo score indicates improvement.
    Mayo Score: Change From Baseline Over Time
    The Mayo score ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment [PGA]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo score indicates improvement.

    Secondary Outcome Measures

    Percentage of Participants With Remission Per Partial Mayo Score Over Time
    The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment [PGA]), each of which ranges from 0 (normal) to 3 (severe disease). Remission was defined as Partial Mayo score ≤ 2 with no subscore > 1.
    Mayo Endoscopy Subscore: Change From Baseline Over Time
    The Mayo Endoscopy subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Endoscopy subscore indicates improvement.
    Mayo Rectal Bleeding Subscore: Change From Baseline Over Time
    The Mayo Rectal Bleeding subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Rectal Bleeding subscore indicates improvement.
    Mayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time
    The Mayo Physician's Global Assessment of Disease Severity subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Physician's Global Assessment of Disease Severity subscore indicates improvement.
    Mayo Stool Frequency Subscore: Change From Baseline Over Time
    The Mayo Stool Frequency subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Stool Frequency subscore indicates improvement.
    Inflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time
    The IBDQ is a 32-item questionnaire that assesses how the subject felt during the 2 weeks before the measurement time point. Questions are related to symptoms the subject might have had as a result of UC, how the subject felt in general, how the subject's mood was, and social and work problems the subject might have that resulted from UC. An increase in IBDQ score indicates less impact of UC on the subject's life. The responses to each question range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
    36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time
    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical [PCS]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
    36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time
    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical [PCS]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
    Work Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    WPAI:GH Impairment While Working: Change From Baseline Over Time
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    WPAI:GH Overall Work Impairment: Change From Baseline Over Time
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    WPAI:GH Activity Impairment: Change From Baseline Over Time
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    Colectomy Rate
    The colectomy rates were estimated using Kaplan-Meier methodology based on the time to first colectomy.
    Health Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations
    The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to ulcerative colitis since the last visit. The cumulative number of unscheduled utilizations over the course of the study is presented.
    Number of Participants With Adverse Events
    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
    Hematology: Mean Change From Baseline to Final Values in Hemoglobin
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Hematology: Mean Change From Baseline to Final Values in Hematocrit
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Hematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Clinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Clinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Clinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Clinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Full Information

    First Posted
    December 12, 2007
    Last Updated
    July 2, 2021
    Sponsor
    AbbVie (prior sponsor, Abbott)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00573794
    Brief Title
    Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
    Official Title
    A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    November 28, 2007 (Actual)
    Primary Completion Date
    December 2016 (Actual)
    Study Completion Date
    December 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    AbbVie (prior sponsor, Abbott)

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Ulcerative Colitis
    Keywords
    Ulcerative Colitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    592 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Adalimumab 40 mg EOW/EW
    Arm Type
    Experimental
    Arm Description
    Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
    Intervention Type
    Biological
    Intervention Name(s)
    adalimumab
    Other Intervention Name(s)
    ABT-D2E7, HUMIRA
    Intervention Description
    adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
    Primary Outcome Measure Information:
    Title
    Partial Mayo Score: Change From Baseline Over Time
    Description
    The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment [PGA]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Partial Mayo score indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Mayo Score: Change From Baseline Over Time
    Description
    The Mayo score ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment [PGA]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo score indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Secondary Outcome Measure Information:
    Title
    Percentage of Participants With Remission Per Partial Mayo Score Over Time
    Description
    The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment [PGA]), each of which ranges from 0 (normal) to 3 (severe disease). Remission was defined as Partial Mayo score ≤ 2 with no subscore > 1.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Mayo Endoscopy Subscore: Change From Baseline Over Time
    Description
    The Mayo Endoscopy subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Endoscopy subscore indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Mayo Rectal Bleeding Subscore: Change From Baseline Over Time
    Description
    The Mayo Rectal Bleeding subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Rectal Bleeding subscore indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Mayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time
    Description
    The Mayo Physician's Global Assessment of Disease Severity subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Physician's Global Assessment of Disease Severity subscore indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Mayo Stool Frequency Subscore: Change From Baseline Over Time
    Description
    The Mayo Stool Frequency subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Stool Frequency subscore indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Inflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time
    Description
    The IBDQ is a 32-item questionnaire that assesses how the subject felt during the 2 weeks before the measurement time point. Questions are related to symptoms the subject might have had as a result of UC, how the subject felt in general, how the subject's mood was, and social and work problems the subject might have that resulted from UC. An increase in IBDQ score indicates less impact of UC on the subject's life. The responses to each question range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time
    Description
    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical [PCS]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time
    Description
    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical [PCS]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Work Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time
    Description
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    WPAI:GH Impairment While Working: Change From Baseline Over Time
    Description
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    WPAI:GH Overall Work Impairment: Change From Baseline Over Time
    Description
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    WPAI:GH Activity Impairment: Change From Baseline Over Time
    Description
    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
    Time Frame
    Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
    Title
    Colectomy Rate
    Description
    The colectomy rates were estimated using Kaplan-Meier methodology based on the time to first colectomy.
    Time Frame
    5 years
    Title
    Health Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations
    Description
    The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to ulcerative colitis since the last visit. The cumulative number of unscheduled utilizations over the course of the study is presented.
    Time Frame
    5 years
    Title
    Number of Participants With Adverse Events
    Description
    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
    Time Frame
    From first dose of study drug until 70 days after the last dose of study drug (up to 398 weeks)
    Title
    Hematology: Mean Change From Baseline to Final Values in Hemoglobin
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Hematology: Mean Change From Baseline to Final Values in Hematocrit
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Hematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Clinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Clinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Clinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Clinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)
    Title
    Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein
    Description
    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
    Time Frame
    Baseline (Week 0), final value (up to 5 years)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject must have successfully enrolled and completed either study M06-826 (NCT00385736) or study M06-827 (NCT00408629) Subject is judged to be in generally good health as determined by the principal investigator Exclusion Criteria: Subject has not responded to weekly adalimumab therapy in M06-826 (NCT00385736) or M06-827 (NCT00408629) Subject considered by the investigator, for any reason, to be an unsuitable candidate Female subject who is pregnant or breast-feeding or considering becoming pregnant
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    AbbVie Inc
    Organizational Affiliation
    AbbVie
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25155227
    Citation
    Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov;109(11):1771-80. doi: 10.1038/ajg.2014.242. Epub 2014 Aug 26.
    Results Reference
    background
    PubMed Identifier
    29380251
    Citation
    Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6.
    Results Reference
    derived
    Links:
    URL
    http://rxabbvie.com
    Description
    Related Info.

    Learn more about this trial

    Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

    We'll reach out to this number within 24 hrs